Seven patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Mar 2035. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2035
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2018 to 2042.20232028203320382042
7 pending applications: term is not computable until grant.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Mar 2035 · High confidence
Also notable
Ends Nov 2039 · High confidence
Amyloid Targeting Agents and Methods of Using the Same
US 10,370,345
The most cited patent in this portfolio, cited by 10 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
Phosphate Compounds for Detecting Neurological Disorders
US 12,708,676
Granted 2026. Too new for citation comparison; protection runs to 2039.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 6 to 8, 2027 · next Feb 6
Recent changes
- 2 of the patents on this record were granted since Aug 17, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Amyloid Targeting Agents and Methods of Using the Same | 5 in force | to Oct 2036 |
| Compositions and Methods for Detection of Traumatic Brain Injury | 1 in force | to Jul 2042 |
| Phosphate Compounds for Detecting Neurological Disorders | 1 in force | to Nov 2039 |
Patents held now
Soonest term end first.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,005,745 | Amyloid Targeting Agents and Methods of Using the Same In force · High confidence | In force | High confidence | |
| US 10,370,345 | Amyloid Targeting Agents and Methods of Using the Same In force · High confidence | In force | High confidence | |
| US 10,934,264 | Amyloid Targeting Agents and Methods of Using the Same In force · High confidence | In force | High confidence | |
| US 11,718,596 | Amyloid Targeting Agents and Methods of Using the Same In force · High confidence | In force | High confidence | |
| US 12,741,949 | Amyloid Targeting Agents and Methods of Using the Same In force · Medium confidence | In force | Medium confidence | |
| US 12,708,676 | Phosphate Compounds for Detecting Neurological Disorders In force · High confidence | In force | High confidence | |
| US 12,478,693 | Compositions and Methods for Detection of Traumatic Brain Injury In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 7 applications pending · 2 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 computed term date comes from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.